Stem cells in pediatric cardiology

European Journal of Pediatrics

Volumn 172, Issue 10, 2013, Pages 1287-1292

  Patel, Pranali ^a   Mital, Seema ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Congenital heart disease; Drug discovery; Induced pluripotent stem cells; Pediatric cardiology; Personalized medicine

Indexed keywords

CALCIUM CHANNEL L TYPE; CLOPIDOGREL; ELASTIN; ROSCOVITINE; TACROLIMUS; TROPONIN T; WARFARIN;

ALAGILLE SYNDROME; AORTA STENOSIS; AORTA SUPRAVALVULAR STENOSIS; CARCINOGENICITY; CARDIOMYOPATHY; CHILDHOOD DISEASE; CONGESTIVE CARDIOMYOPATHY; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; ENVIRONMENTAL FACTOR; FOLLOW UP; GENETIC DIFFERENCE; GENOMIC INSTABILITY; HEART DEVELOPMENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IN VITRO STUDY; LONG QT SYNDROME; PEDIATRIC CARDIOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PLURIPOTENT STEM CELL; POINT MUTATION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SARCOPLASMIC RETICULUM; SMOOTH MUSCLE FIBER; STEM CELL; STEM CELL TRANSPLANTATION;

CARDIOLOGY; CARDIOVASCULAR DISEASES; CHILD; DRUG DISCOVERY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PEDIATRICS; STEM CELL TRANSPLANTATION;

EID: 84885321344     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-012-1920-4     Document Type: Review

References (42)

1. Blume ED, Naftel DC, Bastardi HJ, Duncan BW, Kirklin JK, Webber SA, Investigators ftPHTS (2006) Outcomes of children bridged to heart transplantation with ventricular assist devices. Circulation 113(19):2313-2319
2. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, Anversa P (2011) Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378(9806):1847-1857
3. Braam SR, Tertoolen L, van de Stolpe A, Meyer T, Passier R, Mummery CL (2010) Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 4(2):107-116
4. Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang Y-S, Schaniel C, Lee D-F, Yang L, Kaplan AD, Adler ED, Rozov R, Ge Y, Cohen N, Edelmann LJ, Chang B, Waghray A, Su J, Pardo S, Lichtenbelt KD, Tartaglia M, Gelb BD, Lemischka IR (2010) Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465(7299):808-812
5. Collet J-P, Hulot J-S, Pena A, Villard E, Esteve J-B, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660):309-317
6. Ge X, Ren Y, Bartulos O, Lee MY, Yue Z, Kim K-Y, Li W, Amos PJ, Bozkulak EC, Iyer A, Zheng W, Zhao H, Martin KA, Kotton DN, Tellides G, Park I-H, Yue L, Qyang Y (2012) Modeling supravalvular aortic stenosis syndrome using human induced pluripotent stem cells. Circulation. doi: 10.1161/circulationaha.112. 116996
7. Gerecht S, Burdick JA, Ferreira LS, Townsend SA, Langer R, Vunjak-Novakovic G (2007) Hyaluronic acid hydrogel for controlled self-renewal and differentiation of human embryonic stem cells. Proc Natl Acad Sci 104(27):11298-11303
8. Gijsen V, Mital S, van Schaik RH, Soldin OP, Soldin SJ, van der Heiden IP, Nulman I, Koren G, de Wildt SN (2011) Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J Heart Lung Transplant Off Publ Int Soc Heart Transplant 30(12):1352-1359
9. Hu B-Y, Weick JP, Yu J, Ma L-X, Zhang X-Q, Thomson JA, Zhang S-C (2010) Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci 107(9):4335-4340
10. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L (2011) Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471(7337):225-229
11. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ (2011) Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID)/Clinical Perspective. Circulation 124(3):304-313
12. Ji J, Ng SH, Sharma V, Neculai D, Hussein S, Sam M, Trinh Q, Church GM, McPherson JD, Nagy A, Batada NN (2012) Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells. Stem Cells 30(3):435-440. doi: 10.1002/stem.1011
13. Katz DA, Murray B, Bhathena A, Sahelijo L (2008) Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy. Nat Rev Drug Discov 7(4):293-305
14. Kelly R, Stevens LP, Muskheli V, Murry CE (2009) Scaffold-free human cardiac tissue patch created from embryonic stem cells. Tissue Eng Part A 15(6):1211-1222
15. Kinnear C, Chang WY, Khattak S, Hinek A, Thompson T, Rodrigues DC, Kennedy K, Mahmut N, Pasceri P, Stanford WL, Ellis J, Mital S (2013) Modeling and rescue of the vascular phenotype of Williams-Beuren syndrome in patient induced pluripotent stem cells. Stem Cells Transl Med. doi: 10.5966/sctm.2012- 0054
16. Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT (2007) Influence of CYP2C9 and VKORC1 1173C/T Genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83(2):312-321
17. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O'Malley R, Castanon R, Klugman S, Downes M, Yu R, Stewart R, Ren B, Thomson JA, Evans RM, Ecker JR (2011) Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471(7336):68-73
18. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LEJ, Berman D, Czer LSC, Marbán L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marbán E (2012) Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379(9819):895-904. doi: 10.1016/S0140-6736(12)60195-0
19. Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, Denning C (2011) Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Hear J 32(8):952-962
20. Maury Y, Gauthier M, Peschanski M, Martinat C (2012) Human pluripotent stem cells for disease modelling and drug screening. BioEssays 34(1):61-71. doi: 10.1002/bies.201100071
21. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A, Hohnke C, Hofmann F, Seyfarth M, Sinnecker D, Schomig A, Laugwitz K-L (2010) Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363(15):1397-1409. doi: 10.1056/NEJMoa0908679
22. Ng K-M, Lee Y-K, Lai W-H, Chan Y-C, Fung M-L, Tse H-F, Siu C-W (2011) Exogenous expression of human apoA-I enhances cardiac differentiation of pluripotent stem cells. PLoS One 6(5):e19787
23. Otsuji TG, Minami I, Kurose Y, Yamauchi K, Tada M, Nakatsuji N (2010) Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: qualitative effects on electrophysiological responses to drugs. Stem Cell Res 4(3):201-213
24. 2-Catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLoS One 5(6):e11134
25. Pasca SP, Portmann T, Voineagu I, Yazawa M, Shcheglovitov A, Pasca AM, Cord B, Palmer TD, Chikahisa S, Nishino S, Bernstein JA, Hallmayer J, Geschwind DH, Dolmetsch RE (2011) Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 17(12):1657-1662
26. Pober BR (2010) Williams-Beuren syndrome. N Engl J Med 362(3):239-252
27. Rajamohan D, Matsa E, Kalra S, Crutchley J, Patel A, George V, Denning C (2012) Current status of drug screening and disease modelling in human pluripotent stem cells. BioEssays. doi: 10.1002/bies.201200053
28. Rubin LL (2008) Stem cells and drug discovery: the beginning of a new era? Cell 132(4):549-552
29. Simpson DL, Mishra R, Sharma S, Goh SK, Deshmukh S, Kaushal S (2012) A strong regenerative ability of cardiac stem cells derived from neonatal hearts. Circulation 126(11 suppl 1):S46-S53. doi: 10.1161/circulationaha.111.084699
30. Sun N, Yazawa M, Liu JW, Han L, Sanchez-Freire V, Abilez OJ, Navarrete EG, Hu SJ, Wang L, Lee A, Pavlovic A, Lin S, Chen R, Hajjar RJ, Snyder MP, Dolmetsch RE, Butte MJ, Ashley EA, Longaker MT, Robbins RC, Wu JC (2012) Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 4(130):13. doi: 10.1126/scitranslmed.3003552
31. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676
32. Thomson JA (1998) Embryonic stem cell lines derived from human blastocysts. Science 282:1145-1147
33. Visscher H, Amstutz U, Sistonen J, Ross CJ, Hayden MR, Carleton BC (2011) Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics. J Cardiovasc Pharmacol 58(3):228-239. doi: 10.1097/FJC.1090b1013e3182163b3182182
34. Visscher H, Ross CJD, Rassekh SR, Barhdadi A, Dubé M-P, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AMK, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR, Consortium CPNfDS (2012) Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 30(13):1422-1428
35. Xue T, Cho HC, Akar FG, Tsang S-Y, Jones SP, Marbán E, Tomaselli GF, Li RA (2005) Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes. Circulation 111(1):11-20
36. Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M, Henckaerts E, Bonham K, Abbott GW, Linden RM, Field LJ, Keller GM (2008) Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 453(7194):524-528
37. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, Dolmetsch RE (2011) Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471(7337):230-234
38. Yokoo N, Baba S, Kaichi S, Niwa A, Mima T, Doi H, Yamanaka S, Nakahata T, Heike T (2009) The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun 387(3):482-488
39. Yu J (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-1920
40. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ (2009) Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 104(4):e30-e41
41. Zhu W-Z, Xie Y, Moyes KW, Gold JD, Askari B, Laflamme MA (2010) Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells/novelty and significance. Circ Res 107(6):776-786
42. Zimmermann W-H, Cesnjevar R (2009) Cardiac tissue engineering: implications for pediatric heart surgery. Pediatr Cardiol 30(5):716-723